Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Healthcare Digest of Vermont.
Press releases published on May 10, 2025
Best Vyvanse Alternative Over the Counter for ADHD - Natural Vyvanse Substitute - Noocube
GlobeNewswire
·
May 10, 2025
London, May 10, 2025 (GLOBE NEWSWIRE) -- Vyvanse is a prescription medication that is used to treat ADHD symptoms, but it can be expensive and some people don't like the idea of taking a drug class medicine or stimulant medications. For these reasons …
Akero Therapeutics präsentiert auf dem EASL-Kongress 2025 die Ergebnisse nach 96 Wochen der klinischen Phase-IIb-Studie SYMMETRY zu Efruxifermin bei Patienten mit kompensierter Zirrhose, die durch MASH verursacht wird, und zeigt eine Verbesserung der…
GlobeNewswire
·
May 10, 2025
SOUTH SAN FRANCISCO, Kalifornien, May 10, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), ein in der klinischen Phase tätiges Unternehmen, das bahnbrechende Therapien für Patienten mit schwerwiegenden Stoffwechselkrankheiten entwickelt, …
MEDVi Under Review: Best GLP-1 Semaglutide & Terzepatide Compound Solution for Personalized Weight Loss
GlobeNewswire
·
May 10, 2025
New York, May 10, 2025 (GLOBE NEWSWIRE) -- In This Article, You’ll Discover: The growing challenges with traditional weight loss methods and why most diets fail What GLP-1 receptor agonists like Semaglutide and Tirzepatide are and how they support …
Akero Therapeutics gibt Publikation von „Phase IIb SYMMETRY“-Studie im New England Journal of Medicine bekannt
GlobeNewswire
·
May 10, 2025
Die Ergebnisse stützen den potenziellen Nutzen von Efruxifermin (EFX) für eine Fibrosebesserung unter Patienten mit kompensierter Zirrhose (F4-Fibrose) aufgrund von MASH auf Basis von SYMMETRY-Studiendaten nach 96 Wochen, die auf dem EASL Congress 2025 …
Akero Therapeutics annonce la publication de l’essai de phase 2b SYMMETRY dans le New England Journal of Medicine
GlobeNewswire
·
May 10, 2025
Les résultats confirment le bénéfice potentiel de l’éfruxifermine (EFX) pour déclencher une amélioration de la fibrose chez les patients atteints de cirrhose compensée (fibrose F4) due à une MASH ; les données à 96 semaines de l’essai SYMMETRY ont fait l’ …
Akero Therapeutics and HistoIndex Present New Analyses of Phase 2b HARMONY Trial in Oral and Poster Presentations at the EASL Congress 2025
GlobeNewswire
·
May 10, 2025
Analysis of EFX results with AI-based digital pathology underscores the potential value in evaluating histopathology response Data contribute to growing body of support around the anti-fibrotic activity of EFX in patients with pre-cirrhotic MASH SOUTH SAN …
Sumatra Slim Belly Tonic Reviews: 2025 Real User Reviews Analyzed & Verified (Blue Tonic for Weight Loss)
GlobeNewswire
·
May 10, 2025
LOS ANGELES, May 10, 2025 (GLOBE NEWSWIRE) -- Losing weight these days can feel more difficult than ever. Despite trying countless diets, workout routines, and the latest supplements, many people still struggle with stubborn belly fat that just won't go …
Madrigal Announces New Clinical Data Demonstrating Rezdiffra™ (resmetirom) Significantly Improved Multiple Noninvasive Tests and Portal Hypertension Risk in Patients with Compensated MASH Cirrhosis
GlobeNewswire
·
May 10, 2025
Late-breaking results from the open-label compensated MASH cirrhosis (F4c) arm of the Phase 3 MAESTRO-NAFLD-1 trial presented at the EASL Congress 65% of patients with clinically significant portal hypertension (CSPH) at baseline moved into lower risk …
Best Fat Burners For Men 2025: Top Weight Loss Pills & Supplements For Fast Fat Loss - Wolfson Brands Ltd
GlobeNewswire
·
May 10, 2025
New York City, May 10, 2025 (GLOBE NEWSWIRE) -- Introduction: Why Fat Burners Are a Game-Changer for Men in 2025 Losing weight and building a leaner physique are common goals for men in 2025. But even with the best diet and workout routine, shedding …